Liver Drug Metabolism
Liver Drug Metabolism - Related Videos
06:26
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
0 Views •
Cited by 1 •
2025
Mouse model of metabolic dysfunction-associated steatotic liver disease (MASLD) with metabolic dysfunction, hepatic gene expression changes, and liver histopathological alterations that resemble human MASLD, including fibrosis that progresses to advanced fibrosis stage 3. This model can be used in studies of MASLD pathophysiology and in pre-clinical studies of new therapies.
06:50
Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening
0 Views •
Cited by 1 •
2025
Here, we establish a metabolic profiling platform integrating three-dimensional (3D) glioma spheroids and imaging-based normalization via extracellular flux analysis. This approach enables more accurate assessment of tumor metabolic responses to drug treatments and provides insights into potential mechanisms of resistance.
01:17
Drug Metabolism: Phase I Reactions
0 Views •
2023
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
01:14
Drug Metabolism: Phase II Reactions
0 Views •
2023
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
01:27
Pharmacogenetics of Drug Metabolism: Overview
0 Views •
2026
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
FAQs
The two phases perform different chemical tasks. Phase I reactions such as oxidation, reduction, or hydrolysis introduce or expose functional groups, whereas phase II reactions attach polar molecules, including glucuronide or sulfate. This distinction helps explain why a medicine may undergo sequential processing before becoming more water soluble and ready for transport-based clearance.
Transporters help determine where processed medicines move after enzymatic reactions. They support clearance into bile or into the blood, linking intracellular metabolism with removal from the body. Consequently, enzyme activity alone does not describe the entire disposition of a medicine; transporter activity also contributes to its persistence, elimination route, and clinical behavior.
Chemical modification can change a medicine’s activity and the time it remains available in the body. If these processes alter exposure, the resulting therapeutic response may change, while unwanted effects or toxicity may also become more likely. For this reason, metabolic pathways are central to interpreting differences in treatment outcomes and selecting appropriate dosing.
Clinicians consider metabolic processing because it helps regulate a medicine’s activity, duration, and elimination. Differences in these processes can influence how much medicine is needed and how treatment responds over time. In clinical practice, understanding the relevant pathways supports dosing decisions that account for therapeutic response, possible toxicity, and the medicine’s clearance pattern.
Metabolism is one of the processes through which medicines can influence one another’s clinical behavior. Changes affecting chemical modification or subsequent transport may alter activity, duration, elimination, or toxicity. Evaluating these pathways therefore helps clinicians recognize potential interactions and make safer treatment decisions rather than considering each medicine’s effects in isolation.
During drug development, metabolic pathways provide information about how a candidate medicine may be activated, modified, transported, or eliminated. That information can guide evaluation of therapeutic effects, duration, toxicity, and interactions. In clinical care, the same pathway knowledge supports individualized treatment decisions by connecting metabolic behavior with a patient’s dosing and response needs.